Computer modeling of diabetes and its complications: A report on the fifth Mount Hood challenge meeting

Value in Health

Volumn 16, Issue 4, 2013, Pages 670-685

  Palmer, Andrew J ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

computer simulation; cost effectiveness analysis; diabetes; health economics; modeling

Indexed keywords

ATORVASTATIN; GLICLAZIDE; GLUCOSE; INDAPAMIDE PLUS PERINDOPRIL;

ARTICLE; BLOOD PRESSURE; COMPUTER MODEL; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; HUMANS; RISK;

EID: 84879408596     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.01.002     Document Type: Article

References (25)

1. J.B. Brown, A.J. Palmer, and P. Bisgaard The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 50 Suppl. 3 2000 S57 S64
2. International Diabetes Federation Diabetes Atlas Fourth Edition. Available from: http://www.diabetesatlas.org/content/diabetes-and-impaired- glucose-tolerance. [Accessed May 23, 2011].
3. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46.
4. Mount Hood Modeling Group Web site. Available from: https://sites.google. com/site/mounthoodchallenge/. [Accessed January 17, 2013].
5. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
6. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
7. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
8. ACCORD Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
9. A.J. Palmer, S. Roze, and W.J. Valentine The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making Curr Med Res Opin 20 Suppl. 1 2004 S5 26
10. A.J. Palmer, S. Roze, and W. Valentine Validation of the CORE Diabetes Model against epidemiological and clinical studies Curr Med Res Opin 20 Suppl. 1 2004 S27 S40
11. H. Zhou, D.J.M. Isaman, and S. Messinger A computer simulation model of diabetes progression, quality of life and cost Diabetes Care 28 2005 2835 2863
12. J. Barhak, D.J.M. Isaman, W. Ye, and D. Lee Chronic disease modeling and simulation software J Biomed Inform 43 2010 791 799
13. Asseburg C, Willis M, Persson U, et al. Validation of the IHE/J&J economic simulations model of type 2 diabetes mellitus (T2DM). Presented at the 14th Annual ISPOR International Meeting. May 18, 2009.
14. P.M. Clarke, A.M. Gray, and A. Briggs A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68) Diabetologia 47 2004 1747 1759
15. R.J. Stevens, V. Kothari, and A.I. Adler The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) Clin Sci (Lond) 101 2001 671 679
16. V. Kothari, R.J. Stevens, and A.I. Adler UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine Stroke 33 2002 1776 1781
17. R.J. Stevens, R.L. Coleman, and A.I. Adler Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66 Diabetes Care 27 2004 201 207
18. CDC Diabetes Cost-effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 287 2002 2542 2551
19. Hoerger T.J., Segel J.E., Zhang P., Sorensen S.W. Validation of the CDC-RTI Diabetes Cost-Effectiveness Model. RTI Press Methods Report, 2009. Available from: http://www.rti.org/pubs/mr-0013-0909-hoerger.pdf. [Accessed February 2, 2012].
20. CDC-RTI Diabetes Cost-Effectiveness Model description. Available from: http://care.diabetesjournals.org/content/suppl/2010/06/14/dc10-0554.DC1/ dc100554onlineappendix.pdf. [Accessed February 2, 2012].
21. P. McEwan, K. Bergenheim, and Y. Yuan Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care Pharmacoeconomics 28 2010 665 674
22. P. McEwan, M. Evans, H. Kan, and K. Bergenheim Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model Diabetes Obes Metab 12 2010 431 436
23. P. McEwan, J.R. Peters, K. Bergenheim, and C.J. Currie Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) Curr Med Res Opin 22 2006 121 129
24. S. Blum, M. Vardi, and J.B. Brown Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype Pharmacogenomics 11 2010 675 684
25. Intergovernmental Panel on Climate Change (IPCC) Fourth Assessment Report Climate Change 2007: Working Group I: The Physical Science Basis. Available from: http://www.ipcc.ch/publications-and-data/ar4/wg1/en/ch10.html. [Accessed March 9, 2012].